AstraZeneca asthma drug misses key marker in late-stage trial October 25, 2022 AstraZeneca’s asthma drug failed to significantly improve difficulties swallowing in a late-stage trial, the pharmaceutical giant announced today. The drug, called Fasenra, met just one of two main goals of a stage III study assessing the treatment’s benefits in a chronic allergic condition that causes difficulty in swallowing. The condition, eosinophilic esophagitis, is characterised by [...]
Drop in Covid-19 vaccine demand swings Oxford Biomedica to a loss September 15, 2022 A drop in Covid-19 vaccine demand and manufacturing has swung British biotech firm Oxford Biomedica to a revenue loss in the half of the year. The London-listed firm, which worked with AstraZeneca’s to produce its Covid-19 vaccine, has revenue slip more than 20 per cent to £64m in the six moths to 30 June, down [...]
AstraZeneca share price dips with investors ‘underwhelmed’ by diabetes drug August 30, 2022 AstraZeneca’s share price has dipped into the red today, with investors “underwhelmed” by its diabetes and heart failure drug Fraxiga. The stock sank 1.8 per cent to 11,160p per share by early afternoon. However, the share price has grown 6.2 per cent over the past three months. ‘’Investors appear to have been underwhelmed by the [...]
City Moves: Who’s switching jobs in the Square Mile? August 23, 2022 City A.M.’s Millie Turner provides a roundup of the most important hires and job moves across the City, every morning. Email citymoves@cityam.com to be featured. Knight Frank Property consultancy Knight Frank has appointed a new head of lettings in its King’s Cross office. Joining from the firm’s Canary Wharf office where he was a most recently an associate in the lettings team, [...]
GSK shares float above recent lows amid looming legal woes August 17, 2022 British pharmaceutical giant GlaxoSmithKline (GSK) has been wrapped up with legal woes this week over recalled heartburn drug Zantac and a former AstraZeneca dealmaker – which have wiped billions off its market value. London-listed GSK’s shares have dipped into the red slightly today but remained above recent lows. However, the company has lost nearly eight [...]
UK government must wake up to clinical research slowdown, industry body warns July 31, 2022 A slowdown in clinical research could hold Britain back in its bid to become a life sciences superpower, an industry body has warned. In a letter to Rishi Sunak and Liz Truss, the Association of the British Pharmaceutical Industry (ABPI) said “alarm bells” should be ringing across the government, the Sunday Telegraph reported. The letter [...]
£1.4bn booster results: AstraZeneca’s strong performance paves a runway for growth July 29, 2022 Pharma giant AstraZeneca saw first half revenues rise by 48 per cent to $22.2bn, ignoring the impact of exchange rates, as the company saw growth in all divisions apart from Other Medicines. Excluding the impact of the Alexion acquisition, exchange rates, and other one-off costs, operating profit was 71 per cent higher at £1.4bn. This [...]
Oxford Biomedica extends deal with AstraZeneca to make Covid vaccines beyond 2022 July 1, 2022 Oxford Biomedica have inked a new three-year agreement to make AstraZeneca's COVID-19 vaccine beyond 2022.
NHS agrees to pay £120k in damages to bereaved fiancee in covid first June 21, 2022 A woman whose fiance died after taking the covid jab has claimed to have received the first covid vaccine damage payment of £120,000.
AstraZeneca injects further £100m in Cambridge research centre March 7, 2022 AstraZeneca injects another £100m over budget to complete its Cambridge-based research and development centre. The Discovery Centre, or the ‘Disc’ as it is also known, was formally unveiled in November by Prince Charles and business secretary Kwasi Kwarteng. According to The Times, the site has cost the vaccine-maker £1.1bn, which is more than three times [...]